Eric L Simpson
Overview
Explore the profile of Eric L Simpson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
270
Citations
8418
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cork M, Deleuran M, Geng B, Silverberg J, Simpson E, Stein Gold L, et al.
J Allergy Clin Immunol Pract
. 2025 Mar;
PMID: 40081761
Background: Abrocitinib has a manageable long-term safety profile for patients with moderate-to-severe atopic dermatitis. Identifying populations at higher risk of adverse events (AEs) will help optimize dose selection. Objective: To...
2.
Achieving long-term control in atopic dermatitis: emerging concepts, definitions, flares and therapy
Williams H, Simpson E, Langan S, Roberts A, Thomas K
J Allergy Clin Immunol Pract
. 2025 Feb;
PMID: 39993501
No abstract available.
3.
Eichenfield L, Serrao R, Prajapati V, Browning J, Swanson L, Funk T, et al.
Pediatr Dermatol
. 2025 Feb;
PMID: 39980188
Background/objectives: Efficacy and safety of roflumilast cream 0.15% were demonstrated in patients aged ≥ 6 years with atopic dermatitis (AD) in two Phase 3 trials. This Phase 3 parallel-group, double-blind...
4.
Stander S, Yosipovitch G, Simpson E, Kim B, Kabashima K, Thaci D, et al.
Adv Ther
. 2025 Feb;
PMID: 39969783
Introduction: The treat-to-target concept established goals to guide treatment with systemic therapies in atopic dermatitis (AD), including goals for itch improvement, reported as the most burdensome symptom. The aim of...
5.
Silverberg J, Simpson E, Pink A, Weidinger S, Chan G, Biswas P, et al.
Dermatol Ther (Heidelb)
. 2025 Feb;
15(2):367-380.
PMID: 39903335
Introduction: Primary results of the JADE DARE trial (NCT04345367) demonstrated that abrocitinib was superior to dupilumab in reducing the signs and symptoms of moderate-to-severe atopic dermatitis (AD). This post hoc...
6.
Silverberg J, Eichenfield L, Blauvelt A, Irvine A, Guttman-Yassky E, Langley R, et al.
Br J Dermatol
. 2025 Jan;
PMID: 39847538
Background: Atopic dermatitis (AD) is a chronic inflammatory skin disease, characterized by eczematous skin lesions and pruritus. There is an unmet need for effective first-line systemic therapies with good safety...
7.
Simpson E, Eichenfield L, Papp K, Forman S, Hebert A, Gonzalez M, et al.
Dermatitis
. 2025 Jan;
PMID: 39792455
Safety and efficacy of roflumilast cream 0.15% for atopic dermatitis (AD) were demonstrated in two 4-week phase 3 trials. Evaluate long-term safety, tolerability, and efficacy of roflumilast cream 0.15% in...
8.
Simpson E, Hebert A, Browning J, Serrao R, Sofen H, Brown P, et al.
Dermatol Ther (Heidelb)
. 2025 Jan;
15(1):111-124.
PMID: 39777610
Introduction: Tapinarof is a topical aryl hydrocarbon receptor (AhR) agonist in development for the treatment of atopic dermatitis (AD). In two phase 3 trials (ADORING 1 and 2), tapinarof cream...
9.
Weidinger S, Bewley A, Hong H, Silvestre J, Peris K, Wollenberg A, et al.
Br J Dermatol
. 2024 Dec;
192(3):410-419.
PMID: 39657020
Background: Approved tralokinumab maintenance dosing regimens for treatment of moderate-to-severe atopic dermatitis (AD) include 300 mg every 2 weeks (Q2W) and every 4 weeks (Q4W). Clinicians may consider tralokinumab Q4W...
10.
Simpson E, Augustin M, Thaci D, Misery L, Armstrong A, Blauvelt A, et al.
Am J Clin Dermatol
. 2024 Nov;
26(1):121-137.
PMID: 39546129
Background: Atopic dermatitis (AD) is associated with itch, skin pain, sleep disturbances, and diminished quality of life (QoL). Ruxolitinib (Janus kinase [JAK] 1/JAK2 inhibitor) cream demonstrated efficacy and safety in...